The selective response of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib allowed for the identification of oncogenic EGFR mutations [10–13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.